Genelux sets up up to $100 million at-the-market stock sale program with TD Cowen
Genelux entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that lets the company sell up to $100 million of common stock from time to time through TD Cowen as sales agent or principal. The company is not obligated to sell any shares and may suspend sales at any time, and it plans to use any proceeds for general corporate purposes, including research and development and clinical trial expenses.
Key points
- Aggregate offering price of up to $100 million of common stock, par value $0.001 per share
- TD Cowen compensation of up to 3.0% of gross proceeds from any shares sold, plus certain offering expenses
- Sales are made under Form S-3 registration statement (File No. 333-276847), effective February 13, 2024, with a prospectus supplement to be filed March 19, 2026
- Company is not required to sell any shares and may suspend sales at any time
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.